Optimizing cell lines for a Hepatitis B vaccine
Official title: Task V24: Cell line optimization and pre-master bank generation for a Hepatitis B Virus (HBV) vaccine
Funded at International AIDS Vaccine Initiative · NIH-10269959 · Data updated 2026-11-12
This study is working on making better cell lines to help create a new vaccine for Hepatitis B, so we can fight this virus and related diseases more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International AIDS Vaccine Initiative NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 15, 2018 |
| Project end | May 14, 2028 |
| Funding year | 2020 |
| Award (this year) | $810,077 |
| NIH project number | 272201800010I-0-759302000003-1 |
| Project ID | NIH-10269959 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of Hepatitis B infection, including those with chronic liver disease or those in high-prevalence areas.
✕Less likely to help
Patients who are already vaccinated against Hepatitis B or those with no risk factors for the virus may not benefit from this research.
What this research studies
This research focuses on improving cell lines used to produce a vaccine for Hepatitis B Virus (HBV). It involves developing and optimizing these cell lines to ensure they can effectively produce vaccine components under strict regulatory standards. The project includes planning, feasibility assessments, and compliance with good manufacturing practices (cGMP) for clinical studies. By enhancing the production process, the research aims to facilitate the introduction of a new vaccine that can combat HBV and related infectious diseases.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and accessible vaccine for Hepatitis B, potentially reducing the incidence of this infectious disease.
How similar studies have gone: Previous research has shown success in optimizing cell lines for vaccine production, indicating that this approach has potential for effective outcomes.
Where this research is happening
-
International AIDS Vaccine Initiative
New York, United States Active
Researchers
- Principal investigator: Hassel, Thomas — International AIDS Vaccine Initiative
- Study coordinator: Hassel, Thomas
Related research
Other NIH-funded projects on the same topics.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
HBV prevention in community pharmacies: a first step in a low-resource setting
This pilot project tests whether hepatitis B screening and vaccination can be integrated into everyday community pharmacy services to reach more people.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
HBV safety with long-acting HIV therapy for people with HIV
A study to understand how long-acting HIV meds affect hepatitis B in people living with HIV and how to best monitor and protect them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.